Company intelligence / Profile preview

Ancora

Stanford, California, United Statesancorabiotech.com ↗

Ownership: Private
Development stage: Other

Overview

Ancora Biotech is a biopharmaceutical company focused on developing a novel class of modular protein vaccines and therapeutics. Founded by Dr. Peter Kim, the company utilizes a proprietary platform that enables the rapid design and assembly of complex proteins to address unmet needs in infectious diseases and oncology. Their lead programs include a next-generation COVID-19 vaccine designed for enhanced stability and broad protection, as well as targeted therapies for HER2-positive cancers. By leveraging modularity, Ancora aims to streamline the development of biologics that are easier to manufacture and deploy globally.

Therapeutic areas: Infectious DiseasesOncology
Modalities: ProteinVaccineRecombinant proteinModular protein therapeutics
Industry: Biotech

Partnerships

Stanford University

Beyond the preview

Go deeper on Ancora.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ancora.

Explore the full profile